The network meta‐analysis of “on‐demand” and “daily” use of paroxetine in treating men with premature ejaculation from randomized controlled trials

Abstract

Premature ejaculation (PE) is one of the most common disorders of ejaculatory dysfunction, affecting approximately 5% of men (Althof et al., 2014a). The definition of PE in the International Society for Sexual Medicine (ISSM) guidelines mainly includes the following three aspects: (a) ejaculation that always or nearly always occurs prior to or within about 1 min of vaginal penetration from the first sexual experience (lifelong PE and LPE), OR a clinically significant reduction in latency time, often to about 3 minutes or less (acquired PE, APE); (b) the inability to delay ejaculation on all or nearly all vaginal penetrations; and (c) negative personal consequences, such as distress, bother, frustration and/or the avoidance of sexual intimacy (Althof et al., 2014b). However, Waldinger et al. has put forward two additional subtypes of men who were troubled with their ejaculatory function but did not meet the diagnostic concept for PE and designated them as variable PE (VPE) and